

Ian Galea

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3002536/publications.pdf>

Version: 2024-02-01

84
papers

6,394
citations

147566

31
h-index

69108

77
g-index

88
all docs

88
docs citations

88
times ranked

10417
citing authors

#	ARTICLE	IF	CITATIONS
1	CD8 Tâ€cellâ€mediated cerebellitis directed against Purkinje cell antigen after ipilimumab for small cell lung cancer. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	1.8	5
2	The impact of smoking cessation on multiple sclerosis disease progression. <i>Brain</i> , 2022, 145, 1368-1378.	3.7	16
3	Long-Term Cognitive Outcome following Aneurysmal Subarachnoid Haemorrhage. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2022, 31, 106184.	0.7	8
4	Genome-Wide Association Study of Clinical Outcome After Aneurysmal Subarachnoid Haemorrhage: Protocol. <i>Translational Stroke Research</i> , 2022, 13, 565-576.	2.3	5
5	Auditory outcome following aneurysmal subarachnoid haemorrhage. <i>Journal of the Neurological Sciences</i> , 2022, 434, 120125.	0.3	3
6	Iron Deposition in the Brain After Aneurysmal Subarachnoid Hemorrhage. <i>Stroke</i> , 2022, 53, 1633-1642.	1.0	28
7	Association of Haptoglobin Phenotype With Neurological and Cognitive Outcomes in Patients With Subarachnoid Hemorrhage. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 819628.	1.7	3
8	Riskâ€benefit analysis of COVID-19 vaccines â€” a neurological perspective. <i>Nature Reviews Neurology</i> , 2022, 18, 69-70.	4.9	6
9	Microglial heterogeneity after subarachnoid haemorrhage. <i>Clinical and Translational Discovery</i> , 2022, 2, .	0.2	2
10	004â€.. Physical activity monitoring to assess disability progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A15.2-A15.	0.9	0
11	Blood-brain barrier permeability changes in the first year after alemtuzumab treatment predict 2-year outcomes in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 63, 103891.	0.9	6
12	Zonulin and bloodâ€brain barrier permeability are dissociated in humans. <i>Clinical and Translational Medicine</i> , 2022, 12, .	1.7	4
13	Long-term prognostic counselling in people with multiple sclerosis using an online analytical processing tool. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1442-1450.	1.4	3
14	Spectrum, risk factors and outcomes of neurological and psychiatric complications of COVID-19: a UK-wide cross-sectional surveillance study. <i>Brain Communications</i> , 2021, 3, fcab168.	1.5	33
15	Cervical spinal degenerative disease in multiple sclerosis. <i>European Journal of Neurology</i> , 2021, 28, 2497-2502.	1.7	5
16	Considerations for causality assessment of neurological and neuropsychiatric complications of SARS-CoV-2 vaccines: from cerebral venous sinus thrombosis to functional neurological disorder. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 1144-1151.	0.9	37
17	Neurological manifestations of SARS-CoV-2 infection in hospitalised children and adolescents in the UK: a prospective national cohort study. <i>The Lancet Child and Adolescent Health</i> , 2021, 5, 631-641.	2.7	114
18	COVID-19 Encephalitis with SARS-CoV-2 Detected in Cerebrospinal Fluid Presenting as a Stroke Mimic. <i>Journal of Stroke and Cerebrovascular Diseases</i> , 2021, 30, 105915.	0.7	5

#	ARTICLE	IF	CITATIONS
19	The blood-brain barrier in systemic infection and inflammation. <i>Cellular and Molecular Immunology</i> , 2021, 18, 2489-2501.	4.8	177
20	Eosinophilia during natalizumab treatment: Incidence, risk factors and temporal patterns. <i>Journal of Neuroimmunology</i> , 2021, 361, 577729.	1.1	1
21	CRP (C-Reactive Protein) in Outcome Prediction After Subarachnoid Hemorrhage and the Role of Machine Learning. <i>Stroke</i> , 2021, 52, 3276-3285.	1.0	22
22	Neurofilament light predicts neurological outcome after subarachnoid haemorrhage. <i>Brain</i> , 2021, 144, 761-768.	3.7	22
23	Gadolinium enhancement of cranial nerves: Implications for interstitial fluid drainage from brainstem into cranial nerves in humans. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2021, 118, .	3.3	4
24	Prognostic information for people with MS: Impossible or inevitable?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 771-773.	1.4	5
25	Do people with multiple sclerosis want to discuss their long-term prognosis? A nationwide study in Argentina. <i>Multiple Sclerosis and Related Disorders</i> , 2020, 37, 101445.	0.9	8
26	High-Throughput Urinary Neopterin-to-Creatinine Ratio Monitoring of Systemic Inflammation. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 101-113.	0.6	7
27	Characterising neuropsychiatric disorders in patients with COVID-19 – Authors' reply. <i>Lancet Psychiatry</i> , 2020, 7, 934-935.	3.7	10
28	Physical activity monitoring to assess disability progression in multiple sclerosis. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2020, 6, 205521732097518.	0.5	10
29	Haptoglobin genotype and outcome after spontaneous intracerebral haemorrhage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 298-304.	0.9	4
30	Defining causality in COVID-19 and neurological disorders. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 811-812.	0.9	62
31	CNS inflammatory vasculopathy with antimyelin oligodendrocyte glycoprotein antibodies in COVID-19. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2020, 7, e813.	3.1	54
32	Haemoglobin causes neuronal damage in vivo which is preventable by haptoglobin. <i>Brain Communications</i> , 2020, 2, fcz053.	1.5	39
33	Neurological and neuropsychiatric complications of COVID-19 in 153 patients: a UK-wide surveillance study. <i>Lancet Psychiatry</i> , 2020, 7, 875-882.	3.7	1,005
34	Haptoglobin genotype and outcome after aneurysmal subarachnoid haemorrhage. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 305-313.	0.9	11
35	Study protocol for SFX-01 after subarachnoid haemorrhage (SAS): a multicentre randomised double-blinded, placebo controlled trial. <i>BMJ Open</i> , 2020, 10, e028514.	0.8	23
36	Neuroprotective Role of the Nrf2 Pathway in Subarachnoid Haemorrhage and Its Therapeutic Potential. <i>Oxidative Medicine and Cellular Longevity</i> , 2019, 2019, 1-21.	1.9	47

#	ARTICLE	IF	CITATIONS
37	Genetic determinants of circulating haptoglobin concentration. <i>Clinica Chimica Acta</i> , 2019, 494, 138-142.	0.5	14
38	Hearing impairment after subarachnoid hemorrhage. <i>Annals of Clinical and Translational Neurology</i> , 2019, 6, 420-430.	1.7	6
39	SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 30, 257-261.	0.9	6
40	Haptoglobin genotype and aneurysmal subarachnoid hemorrhage. <i>Neurology</i> , 2019, 92, e2150-e2164.	1.5	15
41	Blood-brain barrier permeability measured using dynamic contrast-enhanced magnetic resonance imaging: a validation study. <i>Journal of Physiology</i> , 2019, 597, 699-709.	1.3	47
42	Permeability of the blood-brain barrier predicts no evidence of disease activity at 2 years after natalizumab or fingolimod treatment in relapsing-remitting multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 902-914.	2.8	11
43	A subarachnoid haemorrhage-specific outcome tool. <i>Brain</i> , 2018, 141, 1111-1121.	3.7	41
44	The blood-brain interface: a culture change. <i>Brain, Behavior, and Immunity</i> , 2018, 68, 11-16.	2.0	16
45	Risk knowledge of people with relapsing-remitting multiple sclerosis – Results of an international survey. <i>PLoS ONE</i> , 2018, 13, e0208004.	1.1	18
46	Do people with multiple sclerosis want to know their prognosis? A UK nationwide study. <i>PLoS ONE</i> , 2018, 13, e0193407.	1.1	24
47	Haemoglobin scavenging in intracranial bleeding: biology and clinical implications. <i>Nature Reviews Neurology</i> , 2018, 14, 416-432.	4.9	103
48	Haptoglobin attenuates haemoglobin associated neurotoxicity in the brain. <i>Proceedings for Annual Meeting of the Japanese Pharmacological Society</i> , 2018, WCP2018, PO2-1-41.	0.0	0
49	The blood-brain barrier in systemic inflammation. <i>Brain, Behavior, and Immunity</i> , 2017, 60, 1-12.	2.0	714
50	The effect of systemic inflammation on human brain barrier function. <i>Brain, Behavior, and Immunity</i> , 2017, 62, 35-40.	2.0	82
51	Haptoglobin Genotype and Outcome after Subarachnoid Haemorrhage: New Insights from a Meta-Analysis. <i>Oxidative Medicine and Cellular Longevity</i> , 2017, 2017, 1-9.	1.9	18
52	Lymphopenia in treatment-naive relapsing multiple sclerosis. <i>Neurology: Neuroimmunology and Neuroinflammation</i> , 2016, 3, e275.	3.1	10
53	Pathophysiology of Lymphatic Drainage of the Central Nervous System. , 2016, , 479-501.		1
54	Outcome and Biomarker Analysis from a Multicenter Phase 2 Study of Ipilimumab in Combination with Carboplatin and Etoposide as First-Line Therapy for Extensive-Stage SCLC. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1511-1521.	0.5	95

#	ARTICLE	IF	CITATIONS
55	Hemeâ€“Hemopexin Scavenging Is Active in the Brain and Associates With Outcome After Subarachnoid Hemorrhage. <i>Stroke</i> , 2016, 47, 872-876.	1.0	46
56	A comparative analysis of Patient-Reported Expanded Disability Status Scale tools. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1349-1358.	1.4	54
57	How Do People with Multiple Sclerosis Experience Prognostic Uncertainty and Prognosis Communication? A Qualitative Study. <i>PLoS ONE</i> , 2016, 11, e0158982.	1.1	50
58	Relapse in multiple sclerosis. <i>BMJ, The</i> , 2015, 350, h1765-h1765.	3.0	44
59	Haemoglobin Scavenging After Subarachnoid Haemorrhage. <i>Acta Neurochirurgica Supplementum</i> , 2015, 120, 51-54.	0.5	15
60	A Novel Phase II Trial of Ipilimumab, Carboplatin and Etoposide (Ice) for the First Line Treatment of Extensive Stage Small Cell Lung Cancer (Sclc). <i>Annals of Oncology</i> , 2014, 25, iv516.	0.6	1
61	CNS inflammation other than multiple sclerosis: How likely is diagnosis?. <i>Neurology</i> , 2014, 82, 1187-1189.	1.5	7
62	Structural Basis for Inflammation-driven Shedding of CD163 Ectodomain and Tumor Necrosis Factor-Î± in Macrophages. <i>Journal of Biological Chemistry</i> , 2014, 289, 778-788.	1.6	69
63	A ^W eb-based tool for personalized prediction of long-term disease course in patients with multiple sclerosis. <i>European Journal of Neurology</i> , 2013, 20, 1107-1109.	1.7	24
64	0830â€“Help! I've become shorter than my wife: a treatable cause of camptocormia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, e1.156-e1.	0.9	0
65	The intrathecal CD163â€“haptoglobinâ€“hemoglobin scavenging system in subarachnoid hemorrhage. <i>Journal of Neurochemistry</i> , 2012, 121, 785-792.	2.1	98
66	CD8 ⁺ Tâ€“cell crossâ€“competition is governed by peptideâ€“MHC class I stability. <i>European Journal of Immunology</i> , 2012, 42, 256-263.	1.6	28
67	Natalizumab for relapsing remitting multiple sclerosis. <i>The Cochrane Library</i> , 2011, , CD007621.	1.5	55
68	Cerebrospinal fluid analysis in the 2010 revised McDonald's multiple sclerosis diagnostic criteria. <i>Annals of Neurology</i> , 2011, 70, 183-183.	2.8	9
69	PO17 Dramatic radiological improvement in isolated neurosarcoidosis treated with infliximab. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, e56-e57.	0.9	0
70	Pathophysiology of the lymphatic drainage of the central nervous system: Implications for pathogenesis and therapy of multiple sclerosis. <i>Pathophysiology</i> , 2010, 17, 295-306.	1.0	116
71	N-methyl-d-aspartate antibody encephalitis: temporal progression of clinical and paraclinical observations in a predominantly non-paraneoplastic disorder of both sexes. <i>Brain</i> , 2010, 133, 1655-1667.	3.7	900
72	Cognitive and behavioural correlates of different domains of psychological adjustment in early-stage multiple sclerosis. <i>Journal of Psychosomatic Research</i> , 2010, 69, 353-361.	1.2	47

#	ARTICLE	IF	CITATIONS
73	Immune-to-brain signalling: The role of cerebral CD163-positive macrophages. <i>Neuroscience Letters</i> , 2008, 448, 41-46.	1.0	22
74	Pearls & Oysters: Resolution of hemichorea following endarterectomy for severe carotid stenosis. <i>Neurology</i> , 2008, 71, e80-2.	1.5	21
75	Corticosteroids for the long-term treatment in multiple sclerosis. <i>The Cochrane Library</i> , 2008, , CD006264.	1.5	40
76	An antigen-specific pathway for CD8 T cells across the blood-brain barrier. <i>Journal of Experimental Medicine</i> , 2007, 204, 2023-2030.	4.2	188
77	What is immune privilege (not)?. <i>Trends in Immunology</i> , 2007, 28, 12-18.	2.9	644
78	What is the blood-brain barrier (not)?. <i>Trends in Immunology</i> , 2007, 28, 5-11.	2.9	484
79	Blood-derived dendritic cells in an acute brain injury. <i>Journal of Neuroimmunology</i> , 2005, 166, 167-172.	1.1	47
80	Mannose receptor expression specifically reveals perivascular macrophages in normal, injured, and diseased mouse brain. <i>Glia</i> , 2005, 49, 375-384.	2.5	160
81	CD163-positive perivascular macrophages in the human CNS express molecules for antigen recognition and presentation. <i>Glia</i> , 2005, 51, 297-305.	2.5	194
82	Biochemical Indices of Renal Osteodystrophy in Dialysis Patients on the Island of Malta. <i>International Urology and Nephrology</i> , 2005, 37, 335-340.	0.6	2
83	Stress and exacerbations in multiple sclerosis: Whether stress triggers relapses remains a conundrum. <i>BMJ: British Medical Journal</i> , 2004, 328, 287-287.	2.4	5
84	Defining Causality in Neurological & Neuropsychiatric COVID-19 Vaccine Complications: What Have We Learnt from Current and Previous Vaccination Campaigns?. <i>SSRN Electronic Journal</i> , 0, , .	0.4	2